Outset Medical reports Q2 EPS (66c), consensus (45c)

Reports Q2 revenue $27.388M, consensus $31.19M. “During the quarter, the number of treatments performed each month on Tablo continued at record levels, as utilization remained high and gross margin materially expanded as it has each quarter for more than 3 years,” said Leslie Trigg, Chair and Chief Executive Officer. “These results reflect the strength and differentiation of Tablo and the positive impact it is having on the lives of patients and providers.